{"schema_version":"secwatch.filing_event.v1","accession":"0001723128-22-000028","form_type":"8-K","ticker":"AMRX","cik":"0001723128","company_name":"Amneal Pharmaceuticals, Inc.","filed_at":"2022-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.814096+00:00","generated_at":"2026-06-24T03:24:39.270769+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"medium","headline":"Amneal Q2 2022: net loss $121M, revenue +5% to $559M; Opana settlement charge $263M","bullets":["Q2 2022 net revenue $559M (+5% YoY); GAAP net loss $121M vs net income $15M in Q2 2021.","Adjusted EBITDA $135M (-6% YoY); adjusted diluted EPS $0.19 vs $0.23 in prior year.","Pre-tax charge of $263M for Opana ER antitrust litigation settlement recorded.","2022 adjusted EBITDA guidance updated; specific figure not disclosed in provided excerpt."],"urls":{"canonical":"https://secwatch.observer/filing/0001723128-22-000028","json":"https://secwatch.observer/filing/0001723128-22-000028.json","markdown":"https://secwatch.observer/filing/0001723128-22-000028.md","text":"https://secwatch.observer/filing/0001723128-22-000028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1723128/000172312822000028/0001723128-22-000028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1723128/000172312822000028/amrx-20220805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T03:24:39.270769+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}